Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2000-09-26
2003-04-22
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009200, C435S006120, C435S069100, C435S252300, C435S320100, C536S023100, C514S002600, C530S350000
Reexamination Certificate
active
06551575
ABSTRACT:
BACKGROUND OF THE INVENTION
Motion sickness is a condition produced by road, sea, air, or space travel, or by interacting with virtual environments. It is caused by the effect of any pronounced movement on the organ of balance in the inner ear or by sensory conflict about body motion as perceived by different receptors (visual, vestibular, and body proprioceptors). Symptoms may include headache, excessive sweating and salivation, loss of appetite, malaise, nausea, vomiting, gastrointestinal disturbances and fatigue. Vertigo is the illusion that one's surroundings or self are spinning, either horizontally or vertically, resulting from a disturbance of the semicircular canals in the inner ear or nerve tracts leading from them. It can be induced by motion, zero gravity or disease, and may be accompanied by vomiting, ringing in the ears and unsteadiness.
Travel related motion sickness is experienced by approximately 1% of air travelers and can be as high as 100% of ocean travelers on heavy seas. Children between the ages of 3 and 12 are the most susceptible. 50% of astronauts experience “space motion sickness” during space travel. While a source of discomfort, motion sickness and vertigo can also result in impaired performance by crew members on ships, planes or spacecraft, by drivers suffering from circulatory ailments, or by users of computer-based virtual environments.
Currently available drugs to treat motion sickness and vertigo produce a variety of undesirable side effects, some producing drowsiness, blurred vision, impaired reaction time and pattern recognition, others negatively affecting mood and sleep.
The genes that play important roles in the proper functioning of the vestibular system remain largely uncharacterized. Identification of such genes can provide methods for screening individuals with genetic susceptibility to motion sickness or vertigo and can also provide targets for developing new therapeutic agents that specifically modulate the expression or activity of genes associated with motion sickness or vertigo. Unfortunately, identification of such genes in mammals can be difficult and time consuming.
Therefore, there is a need to identify drugs that alleviate motion sickness and vertigo without undesirable side effects. There also exists a need to identify genes whose expression or activity is associated with conditions such as motion sickness or vertigo. The present invention satisfies these needs and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides a method of identifying a compound that modulates a mammalian vestibular system. The method consists of administering a test compound to an invertebrate, andmeasuring a geotactic behavior of the invertebrate, where a compound that modulates the geotactic behavior of said invertebrate is characterized as a compound that modulates a mammalian vestibular system. The invention also provides a method of identifying a gene that modulates a mammalian vestibular system consisting of obtaining a first and a second strain of an invertebrate; subjecting the first and second invertebrate strains to conditions in which the first strain exhibits a geotactic behavior different than a geotactic behavior exhibited by the second strain; measuring gene expression levels in the first and second strains, and identifying one or more genes that are differentially expressed in the first strain relative to the second strain, whereby a mammalian gene having substantially the same nucleic acid sequence as the one or more differentially expressed genes modulates the mammalian vestibular system.
REFERENCES:
patent: WO 97/30722 (1997-08-01), None
http:/caat.jhsph.edu/programs/grants/reports/torres.html, (1999).
http://www.cannabis.net/weblife.html (Oct. 2000).
http://www.cavalierdaily.com/ .Archives/1998/Feb./12/hecrack.asp.
http:/www.cling.gu.se/~c15pwall/spiders/spiders.html (Oct. 2000).
http://www.nigms.nih.gov
ews/releases/cocaine.html (Jan. 1998).
http://www.stresstips.com/caffeine.html (1998).
Avraham et al., “Characterization of Unconventional MYO6, the Human Homologue of the Gene Responsible for Deafness in Snell's Waltzer Mice,”Hum. Molec. Genet., 6(8):1225-1231 (1997).
Baloh et al., “Familial Vestibulopathy: A New Dominantly Inherited Syndrome,”Neurology, 44:20-25 (1994).
Barinaga, “News of the Week: New Ion Channel May Yield Clues to Hearing,”Science, 287:2132-2133 (2000).
Bellen, “The Fruit Fly: A Model Organism to Study the Genetics of Alcohol Abuse and Addiction?”Cell, 93:909-912 (1998).
Blake et al., “The Products of Ribbon and Raw Are Necessary for Proper Cell Shape and Cellular Localization of Nonmuscle Myosin in Drosophila,”Dev. Biol., 203:177-188 (1998).
Boonstra, “Growth Factor-Induced Signal Transduction in Adherent Mammalian Cells is Sensitive to Gravity,”FASEB J., 13:S35-S42 (1999).
Brand and Perry, “Drugs Used in Motion Sickness—A Critical Review of the Methods Available for the Study of Drugs of Potential Value in Its Treatment and of the Information Which Has Been Derived by These Methods,”Pharmac. Rev., 18(1):895-924, (1966).
Broughton et al., “Endogenously Inhibited Protein Kinase C in Transgenic Drosophila Embryonic Neuroblasts Down Regulates the Outgrowth of Type I and II Processes of Cultured Mature Neurons,”J. Cell. Biochem., 60:584-599 (1996).
Broughton et al., “Transport of CaM Kinase Along Processes Elicited by Neuronal Contact Evokes an Inhibition of Arborization and Outgrowth inD. melanogasterCultured Neurons,”J. Cell. Biochem., 62:484-494 (1996).
Burg et al., “Genetic and Molecular Identification of a Drosophila Histidine Decarboxylase Gene Required in Photoreceptor Transmitter Synthesis,”EMBO J., 12:911-919 (1993).
Byers, “Osteogenesis Imperfecta,” inConnective Tissue and Its Heritable Disorders, Wiley-Liss, Inc., (1993).
Cashmore et al., “Cryptochromes: Blue Light Receptors for Plants and Animals,”Science, 284:760-765 (1999).
Ceriani et al., “Light-Dependent Sequestration of TIMELESS by CRYPTOCHROME,”Science, 285:553-556 (1999).
Cummings et al., “Chaperone Suppression of Aggregation and Altered Subcellular Proteasome Localization Imply Protein Misfolding in SCA1,”Nat. Genet., 19:148-154 (1998).
Danik et al., “Localization of Sulfated Glycoprotein-2/Clusterin mRNA in the Rat Brain by In Situ Hybridization,”J. Comp. Neurol., 334:209-227 (1993).
Davis et al., “Use of the Teleost Saccule to Identify Genes Involved in Inner Ear Function,”DNA and Cell biol., 14(10):833-839 (1995).
Desai et al., “Receptor Tyrosine Phosphatases Are Required for Motor Axon Guidance in the Drosophila Embryo,”Cell, 84:599-609 (1996).
Doe et al., “The Prospero Gene Specifies Cell Fates in the Drosophila Central Nervous System,”Cell, 65:451-464 (1991).
Donat and Auger, “Familial Periodic Ataxia,”Arch. Neurol., 36:568-569 (1979).
Erlenmeyer-Kimling et al., “Studies in Experimental Behavior Genetics: III. Selection and Hybridization Analyses of Individual Differences in the Sign of Geotaxis,”J. Comp. Physiol. Physchol., 55(5): 722-731, (1962).
Fekete, “Cell Fate Specification in the Inner Ear,”Curr. Opin. Neuro., 6:533-541 (1996).
Franc et al., “Croquemort, A Novel Drosophila Hemocyte/Macrophage Receptor that Recognizes Apoptotic Cells,”Immunity, 4:431-443 (1996).
Fransen et al., “High Prevalence of Symptoms of Menière's Disease in Three Families with a Mutation in the COCH Gene,”Hum. Mol. Genet., 8(8):1425-1429 (1999).
Gertler et al., “Dosage-Sensitive Modifiers of Drosophila Abl Tyrosine Kinase Function: Prospero, a Regulator of Axonal Outgrowth, and Disabled, a Novel Tyrosine Kinase Substrate,”Genes and Develop., 7:441-453 (1993).
Griffith et al., “Inhibition of Calcium/Calmodulin-Dependent Protein Kinase in Drospohila Disrupts Behavioral Plasticity,”Neuron, 10:501-509 (1993).
Guvakova and Surmacz, “The Activated Insulin-Like Growth Factor I Receptor Induces Depolarization in Breast Epithelial Cells Characterized by Actin Filament Disassembly and Tyrosine Dephosphorylation of FAK, Cas, and Paxillin,”Exp. Cell. Res., 251:244-255 (1999).
Helmke et al., “SRC Binding to
Campbell & Flores LLP
Kam Chih-Min
Low Christopher S. F.
Neurosciences Research Foundation Inc.
LandOfFree
Methods for identifying compounds for motion sickness,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying compounds for motion sickness,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying compounds for motion sickness,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3030065